---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009702"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T15:13:31.463703+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal

## Summary
- Entered Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC on March 6, 2026 for product 'KARE Verify' (insurance eligibility & benefits verification).
- Revenue split: 50% to Wellgistics, 50% to PharmTech; term is 36 months unless earlier terminated.
- Wellgistics makes preferred EBV pricing available immediately through EinsteinRx AI hub; expects revenue stream beginning Q2 2026.
- EBV market forecast to grow from $2.39B in 2025 to $3B in 2030 per The Business Research Company.

## SEC filing metadata
- accession: 0001493152-26-009702
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009702
- JSON: https://secwatch.observer/filing/0001493152-26-009702.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009702.txt

## Source-grounded claims
- claim_id: c7b0deac2d209b04a119f4a7bc74f9448c394286
  claim: Wellgistics Health, Inc. entered into Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC (effective 2026-03-06).
  evidence_excerpt: On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/2030763/000149315226009702/0001493152-26-009702-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.